{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:33:16Z","timestamp":1792481596354,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.autrev.2020.102537","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T20:44:58Z","timestamp":1585946698000},"page":"102537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1367,"title":["The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Dennis","family":"McGonagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"O'Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Bridgewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102537_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir\u2013Ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102537_bb0015","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic Juvenile Idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2020.102537_bb0020","series-title":"Systemic juvenile idiopathic arthritis","first-page":"56","volume":"12","author":"Martini","year":"2012"},{"key":"10.1016\/j.autrev.2020.102537_bb0025","series-title":"Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell?","first-page":"305","volume":"7","author":"Behrens","year":"2008"},{"key":"10.1016\/j.autrev.2020.102537_bb0030","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0035","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102537_bb0040","article-title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","volume":"102523","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102537_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102537_bb0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.autrev.2020.102537_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102537_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3476(96)70408-0","article-title":"Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine","volume":"128","author":"Ravelli","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2020.102537_bb0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3899\/jrheum.100996","article-title":"An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"38","author":"Davi","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102537_bb0070","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis","volume":"34","author":"de Benedetti","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102537_bb0075","series-title":"A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria","first-page":"1142","volume":"13","author":"Poddighe","year":"2014"},{"key":"10.1016\/j.autrev.2020.102537_bb0080","series-title":"sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia","first-page":"177","volume":"60","author":"Colafrancesco","year":"2014"},{"key":"10.1016\/j.autrev.2020.102537_bb0085","series-title":"The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome","first-page":"185","volume":"11","author":"Ros\u00e1rio","year":"2013"},{"key":"10.1016\/j.autrev.2020.102537_bb0090","series-title":"Eppur Si Muove: ferritin is essential in modulating inflammation","first-page":"149","volume":"191","author":"Sharif","year":"2018"},{"key":"10.1016\/j.autrev.2020.102537_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-016-0130-4","article-title":"Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome","volume":"15","author":"Bracaglia","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.autrev.2020.102537_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0105","article-title":"Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)","author":"Wan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.autrev.2020.102537_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2020.102537_bb0115","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102537_bb0120","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.autrev.2020.102537_bb0125","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with Tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102537_bb0130","article-title":"A pathological report of three COVID-19 cases by minimally invasive autopsies","volume":"49","author":"Yao","year":"2020","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.autrev.2020.102537_bb0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.autrev.2020.102537_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102537_bb0145","series-title":"Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1\u03b2 and IL-6 levels are consistent and efficient predictors of outcome over time","first-page":"1062","volume":"107","author":"Meduri","year":"1995"},{"key":"10.1016\/j.autrev.2020.102537_bb0150","series-title":"Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome","first-page":"1303","volume":"108","author":"Meduri","year":"1995"},{"key":"10.1016\/j.autrev.2020.102537_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrrheum.2013.101","article-title":"How should we approach classification of autoinflammatory diseases?","volume":"9","author":"Grateau","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102537_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpeds.2017.07.025","article-title":"Primary hemophagocytic lymphohistiocytosis and macrophage activation syndrome: the importance of timely clinical differentiation","volume":"189","author":"Grom","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2020.102537_bb0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.14144","article-title":"Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options","volume":"174","author":"Brisse","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2020.102537_bb0175","series-title":"Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019","author":"Chen","year":"2020"},{"key":"10.1016\/j.autrev.2020.102537_bb0180","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/JVI.01782-06","article-title":"Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists","volume":"81","author":"Kopecky-Bromberg","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.autrev.2020.102537_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045842","article-title":"Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model","volume":"7","author":"Cameron","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2020.102537_bb0190","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0195","series-title":"Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)","first-page":"11","volume":"329","author":"Sainz","year":"2004"},{"key":"10.1016\/j.autrev.2020.102537_bb0200","series-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","first-page":"1","author":"Zheng","year":"2020"},{"key":"10.1016\/j.autrev.2020.102537_bb0205","series-title":"Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes","first-page":"386","volume":"9","author":"Zhang","year":"2020"},{"key":"10.1016\/j.autrev.2020.102537_bb0210","series-title":"Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity","first-page":"469","volume":"9","author":"Chen","year":"2020"},{"key":"10.1016\/j.autrev.2020.102537_bb0215","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/jmv.20556","article-title":"Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections","volume":"78","author":"Okabayashi","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.autrev.2020.102537_bb0220","series-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","first-page":"143","volume":"122","author":"Mihara","year":"2012"},{"key":"10.1016\/j.autrev.2020.102537_bb0225","series-title":"IL-6 transsignaling: the in vivo consequences","first-page":"241","volume":"25","author":"Jones","year":"2005"},{"key":"10.1016\/j.autrev.2020.102537_bb0230","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.1302470","article-title":"Blockade of IL-6 <em>trans<\/em> Signaling attenuates pulmonary fibrosis","volume":"193","author":"Le","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102537_bb0235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-3083.2006.01750.x","article-title":"Interleukin-6 trans-signalling in chronic inflammation and cancer","volume":"63","author":"Scheller","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.autrev.2020.102537_bb0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4939-7568-6_11","article-title":"Dissecting Interleukin-6 classic- and trans-signaling in inflammation and cancer","volume":"1725","author":"Garbers","year":"2018","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"10.1016\/j.autrev.2020.102537_bb0245","series-title":"The role of interleukin 6 during viral infections","first-page":"1057","volume":"10","author":"Velazquez-Salinas","year":"2019"},{"key":"10.1016\/j.autrev.2020.102537_bb0250","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0255","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2005477","article-title":"Covid-19 \u2014 the search for effective therapy","author":"Baden","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0295","article-title":"Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model","volume":"12","author":"Bracaglia","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.autrev.2020.102537_bb0300","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2020.102537_bb0305","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1136\/ard.59.suppl_1.i17","article-title":"Targeting interleukin 18 with interleukin 18 binding protein","volume":"59","author":"Dinarello","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102537_bb0310","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102537_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2020.102537_bb0320","series-title":"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","author":"Registry","year":"2020"},{"key":"10.1016\/j.autrev.2020.102537_bb0325","first-page":"137","article-title":"Primary and secondary hemophagocytic lymphohistiocytosis: clinical features","volume":"6","author":"Gupta","year":"2010","journal-title":"Pathogen Ther"},{"key":"10.1016\/j.autrev.2020.102537_bb0330","series-title":"Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis","first-page":"3755","volume":"193","author":"Le","year":"2014"},{"key":"10.1016\/j.autrev.2020.102537_bb0345","series-title":"SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-\u03baB pathway in human monocyte macrophages in vitro","first-page":"19","volume":"142","author":"Dosch","year":"2009"},{"key":"10.1016\/j.autrev.2020.102537_bb0350","series-title":"Up-regulation of IL-6 and TNF-\u03b1 induced by SARS-coronavirus spike protein in murine macrophages via NF-\u03baB pathway","first-page":"1","volume":"128","author":"Wang","year":"2007"},{"key":"10.1016\/j.autrev.2020.102537_bb0355","series-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","first-page":"181","volume":"19","author":"Channappanavar","year":"2016"},{"key":"10.1016\/j.autrev.2020.102537_bb0360","series-title":"Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung","first-page":"258","volume":"5","author":"Dienz","year":"2012"},{"key":"10.1016\/j.autrev.2020.102537_bb0365","series-title":"IL-6 ameliorates acute lung injury in influenza virus infection","first-page":"1","volume":"7","author":"Yang","year":"2017"},{"key":"10.1016\/j.autrev.2020.102537_bb0370","first-page":"589","article-title":"Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance","volume":"28","author":"Murphy","year":"2008"},{"key":"10.1016\/j.autrev.2020.102537_bb0375","series-title":"Intratracheal IL-6 protects against lung inflammation in direct, but not indirect, causes of acute lung injury in mice","volume":"8","author":"Bhargava","year":"2013"},{"key":"10.1016\/j.autrev.2020.102537_bb0380","first-page":"64","article-title":"Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury","volume":"18","author":"Voiriot","year":"2017"},{"key":"10.1016\/j.autrev.2020.102537_bb0385","series-title":"Lethal tuberculosis in interleukin-6-deficient mutant mice","first-page":"4843","volume":"65","author":"Ladel","year":"1997"},{"key":"10.1016\/j.autrev.2020.102537_bb0390","series-title":"Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia","first-page":"439","volume":"176","author":"van der Poll","year":"1997"},{"key":"10.1016\/j.autrev.2020.102537_bb0395","series-title":"Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pulmonary aspergillosis","first-page":"610","volume":"184","author":"Cenci","year":"2001"},{"key":"10.1016\/j.autrev.2020.102537_bb0400","series-title":"Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis","first-page":"99","volume":"16","author":"Kobayashi","year":"2015"},{"key":"10.1016\/j.autrev.2020.102537_bb0405","series-title":"Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-\u03baB\/JNK: a possible role of P-glycoprotein","first-page":"215","volume":"28","author":"Ibrahim","year":"2020"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:17:55Z","timestamp":1761599875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1568997220300926"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102537","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102537"}}